Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yu-Tzu Tai

Showing results (151-160 of 211) with videos related to

Pageof 22
Sort By:
Molecular Cancer Therapeutics|April 15, 2018
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of ElotuzumabAhmed T Kurdi, Siobhan V Glavey, Natalie A Bezman, et al.
Plos One|December 3, 2015
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma CellsRikio Suzuki, Shohei Kikuchi, Takeshi Harada, et al.
Blood|April 17, 2010
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myelomaRao H Prabhala, Dheeraj Pelluru, Mariateresa Fulciniti, et al.
British Journal of Haematology|March 25, 2010
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivoKihyun Kim, Sun-Young Kong, Mariateresa Fulciniti, et al.
Blood|October 22, 2010
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myelomaMoshe E Gatt, Jian-Jun Zhao, Margaret S Ebert, et al.
Blood|April 13, 2010
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Teru Hideshima, et al.
Nature Communications|January 6, 2016
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survivalHiroto Ohguchi, Teru Hideshima, Manoj K Bhasin, et al.
Leukemia|May 12, 2018
Long intergenic non-coding RNAs have an independent impact on survival in multiple myelomaMehmet Kemal Samur, Stephane Minvielle, Annamaria Gulla, et al.
Cancer Research|March 7, 2014
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathwayJian-Jun Zhao, Jianhong Lin, Di Zhu, et al.
Cancer Research|August 8, 2015
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple MyelomaJian-Jun Zhao, Zhang-Bo Chu, Yu Hu, et al.
Pageof 22

Showing results (151-160 of 211) with videos related to

Sort By:
Pageof 22
Molecular Cancer Therapeutics|April 15, 2018
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of ElotuzumabAhmed T Kurdi, Siobhan V Glavey, Natalie A Bezman, et al.
Plos One|December 3, 2015
Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma CellsRikio Suzuki, Shohei Kikuchi, Takeshi Harada, et al.
Blood|April 17, 2010
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myelomaRao H Prabhala, Dheeraj Pelluru, Mariateresa Fulciniti, et al.
British Journal of Haematology|March 25, 2010
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivoKihyun Kim, Sun-Young Kong, Mariateresa Fulciniti, et al.
Blood|October 22, 2010
MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myelomaMoshe E Gatt, Jian-Jun Zhao, Margaret S Ebert, et al.
Blood|April 13, 2010
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myelomaGüllü Görgün, Elisabetta Calabrese, Teru Hideshima, et al.
Nature Communications|January 6, 2016
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survivalHiroto Ohguchi, Teru Hideshima, Manoj K Bhasin, et al.
Leukemia|May 12, 2018
Long intergenic non-coding RNAs have an independent impact on survival in multiple myelomaMehmet Kemal Samur, Stephane Minvielle, Annamaria Gulla, et al.
Cancer Research|March 7, 2014
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathwayJian-Jun Zhao, Jianhong Lin, Di Zhu, et al.
Cancer Research|August 8, 2015
Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple MyelomaJian-Jun Zhao, Zhang-Bo Chu, Yu Hu, et al.
Pageof 22